Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-2263
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-26T06:45:33.705772Z
status: published
lens: g_space
sector: health
headline: scGlycoAI: Machine learning analysis of single-cell glycan and RNA sequencing data for cell-type annotation and malignancy-associated glycan discovery
dek: Single-cell glycan and RNA sequencing (scGR-seq) enables characterization of cellular glycan heterogeneity. Here, we present scGlycoAI, an interpretable machine learning framework that integrates scGR-seq data for glycan-centered biological discovery. Using lectin-binding profiles as input, scGlycoAI employs hierarchical machine learning to accurately classify cell types and subtypes within complex tumor microenvironments. Applied to pancreatic ductal adenocarcinoma (PDAC) datasets, scGlycoAI achieved an overall…
gain_title: Using only glycan lectin-binding features, the model sorted pancreatic cancer cells into eight classes and singled out PVL lectin binding as a marker of aggressive cancer states.
problem_title: (none)
trace_subject: (none)
gain_reading: Using only glycan lectin-binding features, the model sorted pancreatic cancer cells into eight classes and singled out PVL lectin binding as a marker of aggressive cancer states.
gain_evidence: achieved an overall eight-class classification accuracy of 90.3% under leave-one-patient-out validation using glycan features alone | identified PVL lectin binding
problem_reading: (none)
problem_evidence: (none)
quick_read: Researchers built scGlycoAI, an interpretable machine learning framework that uses single-cell glycan and RNA sequencing data. Trained on lectin-binding profiles from pancreatic ductal adenocarcinoma datasets, it classified cell types and subtypes in complex tumor microenvironments.

The work matters because it suggests glycan signatures, though lower-dimensional than transcriptomic data, can annotate cells and point to malignancy-linked biology. The findings are associations rather than proof of therapeutic benefit, and biomarker or treatment uses remain prospects rather than demonstrated outcomes.
limitation: The survival finding is an association in the TCGA cohort, and the authors only suggest the framework could support future biomarker discovery and glycan-targeted therapy development.
tag: Evidence-backed gain
key_points: scGlycoAI uses hierarchical machine learning on lectin-binding profiles to classify cell types and subtypes in tumor microenvironments. | In pancreatic ductal adenocarcinoma data it reached 90.3% eight-class accuracy under leave-one-patient-out validation using glycan features alone. | PVL lectin binding, reflecting sialylated and/or GlcNAc-containing glycans, emerged as a key feature of aggressive cancer states. | Higher expression of the PVL-associated gene signature was associated with poorer overall survival in the TCGA pancreatic adenocarcinoma cohort.
rundown: The framework combines single-cell glycan and RNA sequencing, so glycan binding can be linked to gene activity in the same cells. Leave-one-patient-out validation tests whether the model generalizes to patients not used in training.

A neural-network model with SHAP-based interpretation tied elevated PVL binding to transcriptional programs including epithelial-mesenchymal transition, KRAS signaling, extracellular matrix remodeling, and inflammatory responses.

The authors describe the framework as a foundation for glycan-centered biomarker discovery and glycan-targeted therapeutic development, which is a stated prospect rather than a tested clinical result.
sources:
- peer_reviewed | Glycobiology | https://doi.org/10.1093/glycob/cwag100 | 2026-10-24
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

72db609719dbcf4a194ca5369e0ef717229c49574a0256814191fceee65be99f

previous

0000000000000000000000000000000000000000000000000000000000000000